ISLAMABAD, July 22 (online): As more and more states have been legalizing products derived from cannabis, the Food and Drug Administration (FDA) were keen to answer the question: How many of these product labels accurately report their content?
lawmakers have increasingly been legalizing products derived from cannabis, most often allowing their consumption for medical purposes, and in some cases, recreational use.
However, with increased legalization, specialists have raised concerns regarding potential risks, particularly those linked to the use of unregulated cannabis-derived products.
Such products can contain one or two of the main active compounds present in cannabis: cannabidiol (CBD) and delta-9-tetrahydrocannabinol (THC).
While both of these substances interact with the same receptors in the human body once ingested, they can produce different effects. While CBD is unlikely to lead to a “high,” THC is a psychoactive substance that can elicit this response.
So far, products containing CBD have not been consistently regulated. Recently, the Food and Drug Administration (FDA) have been working to address this issue, to help protect consumer health.
The FDA tested 147 product samples claiming to contain CBD, which were marketed for human or pet use. They conducted these inspections between 2014–2019.
Initial laboratory tests took place between 2014–2018, during which the agency tested 78 products. The FDA selected goods for testing based on manufacturers or sellers that they did not consider to be credible.
Specifically, the agency examined products manufactured by companies known to:
- make unsubstantiated health claims
- sell products reported to cause adverse effects
- sell products online
- produce and sell products across several states.
Stay tuned to Baaghi TV for latest news and updates!
